Bye bye Bapi
We were disappointed to read this yesterday: Pfizer ($PFE) and Johnson & Johnson ($JNJ) have nixed development of one of the most closely watched drugs in their pipelines, bapineuzumab, after two Phase…
We were disappointed to read this yesterday: Pfizer ($PFE) and Johnson & Johnson ($JNJ) have nixed development of one of the most closely watched drugs in their pipelines, bapineuzumab, after two Phase…
One again, Bruce Booth published a terrific post entitled Contrarian Opportunities in Biotech Venture. The crux of the article is that while big pharma is licensing in areas such as…
Last week, the NY Times published an interesting article on the cause of Alzheimer's Disease. The article describes experiments in a new mouse model which may confirm, once and for…